Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2012 1
2013 3
2014 5
2015 6
2016 5
2017 6
2018 6
2019 5
2020 1
2021 1
2022 2
2023 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Yellow fever.
Monath TP, Vasconcelos PF. Monath TP, et al. J Clin Virol. 2015 Mar;64:160-73. doi: 10.1016/j.jcv.2014.08.030. Epub 2014 Oct 24. J Clin Virol. 2015. PMID: 25453327 Review.
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. Levine MM, et al. Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
Estimating cholera incidence with cross-sectional serology.
Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, Kabir A, Gurwith M, Weil AA, Harris JB, Calderwood SB, Ryan ET, Qadri F, Leung DT. Azman AS, et al. Sci Transl Med. 2019 Feb 20;11(480):eaau6242. doi: 10.1126/scitranslmed.aau6242. Sci Transl Med. 2019. PMID: 30787170 Free PMC article.
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.
Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. Gurwith M, et al. Lancet Infect Dis. 2013 Mar;13(3):238-50. doi: 10.1016/S1473-3099(12)70345-6. Epub 2013 Jan 29. Lancet Infect Dis. 2013. PMID: 23369412 Free PMC article. Clinical Trial.
CD4+ T Cell Responses to Toxoplasma gondii Are a Double-Edged Sword.
El Bissati K, Krishack PA, Zhou Y, Weber CR, Lykins J, Jankovic D, Edelblum KL, Fraczek L, Grover H, Chentoufi AA, Singh G, Reardon C, Dubey JP, Reed S, Alexander J, Sidney J, Sette A, Shastri N, McLeod R. El Bissati K, et al. Vaccines (Basel). 2023 Sep 14;11(9):1485. doi: 10.3390/vaccines11091485. Vaccines (Basel). 2023. PMID: 37766162 Free PMC article.
Protein nanovaccine confers robust immunity against Toxoplasma.
El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Roberts CW, Lanar DE, Reed S, Fox C, Carter D, Alexander J, Sette A, Sidney J, Lorenzi H, Begeman IJ, Burkhard P, McLeod R. El Bissati K, et al. NPJ Vaccines. 2017 Sep 5;2:24. doi: 10.1038/s41541-017-0024-6. eCollection 2017. NPJ Vaccines. 2017. PMID: 29263879 Free PMC article.
Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, Blackwelder WC, Traoré A, Tamboura B, Doumbia M, Diallo F, Coulibaly F, Onwuchekwa U, Kodio M, Tennant SM, Reymann M, Lam DF, Gurwith M, Lock M, Yonker T, Smith J, Simon JK, Levine MM. Sow SO, et al. Clin Vaccine Immunol. 2017 Dec 5;24(12):e00265-17. doi: 10.1128/CVI.00265-17. Print 2017 Dec. Clin Vaccine Immunol. 2017. PMID: 29021299 Free PMC article. Clinical Trial.
Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.
Klug B, Robertson JS, Condit RC, Seligman SJ, Laderoute MP, Sheets R, Williamson AL, Gurwith M, Kochhar S, Chapman L, Carbery B, Mac LM, Chen RT; Brighton Collaboration Viral Vaccine Vector Safety Working Group. Electronic address: brightoncollaborationv3swg@gmail.com. Klug B, et al. Vaccine. 2016 Dec 12;34(51):6617-6625. doi: 10.1016/j.vaccine.2016.02.015. Epub 2016 Jun 15. Vaccine. 2016. PMID: 27317264 Free PMC article. Review.
40 results